ENHANCING ONCOLOGY EXPLORATION WITH INTEGRATED KRAS ASSAY COMPANIES AND RAS ASSAYS

while in the speedily evolving field of oncology study, accurate and effective mutation screening is very important for building focused therapies. The KRAS companies System plays a pivotal job On this landscape by offering detailed remedies for KRAS mutation profiling and Assessment. KRAS mutations, present in roughly ninety five% of RAS-relevant